Dex Liquidating (CRDC) 10-Q 5 Feb 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Dec. 31, 2013	Feb. 03, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CARDICA INC	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--06-30	'
Entity Common Stock, Shares Outstanding	'	51,593,777
Amendment Flag	'false	'
Entity Central Index Key	'0001178104	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Condensed_Balance_Sheets_Unaud

Condensed Balance Sheets (Unaudited) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$4,843	$6,373
Short-term investments	1,670	6,022
Accounts receivable, net of allowance of $0 and $33	337	391
Inventories	1,387	1,457
Prepaid expenses and other current assets	165	253
Total current assets	8,402	14,496
Property and equipment, net	2,559	3,161
Restricted cash	104	104
Total assets	11,065	17,761
Current liabilities:	'	'
Accounts payable	1,075	764
Accrued compensation	555	600
Other accrued liabilities	409	420
Current portion of deferred revenue	403	444
Total current liabilities	2,442	2,228
Deferred revenue, net of current portion	1,610	1,610
Note payable	2,935	2,788
Other non-current liabilities	144	161
Total liabilities	7,131	6,787
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value: 5,000,000 shares authorized: no shares issued and outstanding at December 31, 2013, and June 30, 2013	0	0
Common stock, $0.001 par value: 125,000,000 and 75,000,000 shares authorized, 51,482,524 and 51,068,614 shares issued and outstanding, at December 31, 2013, and June 30, 2013, respectively	51	51
Additional paid-in capital	165,952	165,085
Treasury stock at cost (66,227 shares at December 31, 2013, and June 30, 2013)	-596	-596
Accumulated comprehensive loss	-1	-5
Accumulated deficit	-161,472	-153,561
Total stockholders' equity	3,934	10,974
Total liabilities and stockholders' equity	$11,065	$17,761

Condensed_Balance_Sheets_Unaud1

Condensed Balance Sheets (Unaudited) (Parentheticals) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance (in Dollars)	$0	$33
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	75,000,000
Common stock, shares issued	51,482,524	51,068,614
Common stock, shares outstanding	51,482,524	51,068,614
Treasury stock shares	66,227	66,227

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net revenue:	'	'	'	'
Product sales, net	$835	$773	$1,581	$1,555
License and development revenue	'	84	41	168
Royalty revenue	16	17	34	36
Total net revenue	851	874	1,656	1,759
Operating costs and expenses:	'	'	'	'
Cost of product sales	1,054	968	2,055	1,600
Research and development	1,689	2,274	3,346	4,826
Selling, general and administrative	2,186	1,712	3,954	3,447
Total operating costs and expenses	4,929	4,954	9,355	9,873
Loss from operations	-4,078	-4,080	-7,699	-8,114
Interest income	1	4	5	9
Interest expense	-125	-114	-247	-225
Other expense, net	30	-2	30	-2
Net loss	($4,172)	($4,192)	($7,911)	($8,332)
Basic and diluted net loss per share (in Dollars per share)	($0.08)	($0.11)	($0.15)	($0.23)
Shares used in computing basic and diluted net loss per share (in Shares)	51,314	36,951	51,201	36,837

Condensed_Statements_of_Compre

Condensed Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net loss	($4,172)	($4,192)	($7,911)	($8,332)
Changes in market value of investments:	'	'	'	'
Change in unrealized gain (loss) on short term investments, net	1	3	4	4
Comprehensive loss	($4,171)	($4,189)	($7,907)	($8,328)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Operating activities:	'	'
Net loss	($7,911)	($8,332)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	699	445
Amortization of premiums on marketable securities	68	'
Stock-based compensation expense	534	549
Allowance for doubtful account	-33	'
Non cash interest expense	147	123
Changes in operating assets and liabilities:	'	'
Accounts receivable	87	-144
Prepaid expenses and other current assets	88	10
Inventories	70	-423
Accounts payable and other accrued liabilities	283	263
Accrued compensation	-45	100
Deferred revenue	-41	-168
Net cash used in operating activities	-6,054	-7,577
Investing activities:	'	'
Purchases of property and equipment	-97	-1,228
Proceeds from maturities of short-term investments	6,985	6,734
Purchases of short-term investments	-2,697	-3,392
Net cash provided by investing activities	4,191	2,114
Financing activities:	'	'
Net proceeds from issuances of common stock	333	817
Net decrease in cash and cash equivalents	-1,530	-4,646
Cash and cash equivalents at beginning of period	6,373	8,472
Cash and cash equivalents at end of period	4,843	3,826
Supplemental disclosure of cash flow information:	'	'
Interest paid	$100	$100

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Cardica, Inc. (“Cardica” or the “Company”) was incorporated in the state of Delaware on October 15, 1997, as Vascular Innovations, Inc. On November 26, 2001, the Company changed its name to Cardica, Inc.  Historically, the Company’s business focused on the design, manufacture and marketing of proprietary automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. The Company has expanded and re-focused its business by emphasizing the development of a laparoscopic microcutter product line intended for use by thoracic, bariatric, colorectal and general surgeons.
	The Company is developing a microcutter product line based on its proprietary “staple-on-a-strip” technology, which expands its commercial opportunity into additional surgical markets. The Company’s microcutter product line consists of the currently commercially-available MicroCutter XCHANGE™ 30, a cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line, and products in development, including the MicroCutter XCHANGE™ 45, a cartridge based microcutter device with an 8 millimeter shaft and a 45 millimeter staple line, the MicroCutter XPRESS® 30, a true multi-fire endolinear stapling device, the MicroCutter FLEXCHANGE™ 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling, and the MicroCutter XPRESS® 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line specifically designed for the bariatric and thoracic surgery markets.
	The Company completed the design verification for and applied Conformité Européenne (the “CE Mark”) to the MicroCutter XCHANGE 30 in March 2012. The Company only received United States Food and Drug Administration (“FDA”) clearance,for the MicroCutter XCHANGE 30 and blue cartridge in January 2014, for use in multiple open or minimally-invasive surgical procedures for the transection, resection and/or creation of anastomoses in the small and large intestine, as well as the transection of the appendix. The blue cartridge is for use in medium thickness tissue. The Company submitted to the FDA a 510(k) for the white cartridge for use in thin tissue in the first quarter of calendar 2014. As part of the Company’s controlled commercial launch, on December 26, 2012, the Company made its first shipment to its distributor in Europe. The Company now has agreements with four distributors in Europe covering eight countries. The Company will continue to make enhancements and improvements to the MicroCutter XCHANGE 30 based on feedback from surgeons.
	To date, the Company generated product revenues almost exclusively from the sale of automated anastomotic systems, and has generated minimal revenues from the commercial sales of the MicroCutter XCHANGE 30, as it was introduced to the European market in December 2012. For the six months ended December 31, 2013, the Company generated net revenue of $1.7 million, including, $1.6 million from automated anastomotic systems and $79,000 from commercial sales of the MicroCutter XCHANGE 30.
	Need for Additional Capital
	The Company has incurred cumulative net losses of $161.5 million through December 31, 2013, and negative cash flows from operating activities and expects to incur losses for the next several years. Management plans to continue to finance the Company’s operations with equity or debt issuances or through collaboration arrangements. There is no guarantee that such funding will be available to the Company on acceptable terms, or at all, or that such funding will be received in a timely manner, if at all. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate one or more of its development or commercialization programs. There is no guarantee that the Company will be able to reduce its expenditures without materially and adversely affecting the business. These conditions, among other factors, raise substantial doubt about the Company’s ability to continue as a going concern.
	The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty related to the Company’s ability to continue as a going concern.
	Basis of Presentation
	The accompanying unaudited condensed financial statements of Cardica have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for the fair statement of balances and results have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period.
	The accompanying condensed financial statements should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended June 30, 2013, included in the Company’s Form 10-K filed with the Securities and Exchange Commission on September 25, 2013.
	Recently Issued Accounting Standards
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”), relating to Income Taxes (Topic 740), which provides guidance on the presentation of unrecognized tax benefits. The intent of ASU 2013-11 is to better reflect the manner in which an entity would settle at the reporting date any additional income taxes that would result from the disallowance of a tax position when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of ASU 2013-11 is not expected to have a material impact on the Company’s financial statements.
	In February 2013, the FASB issued ASU No. 2013-012, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income, which requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified in their entirety to net income. An entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. The Company adopted ASU No. 2013-02 in July 2013, and as a result, there was no material impact on the Company’s financial statements for the three and six months ended December 31, 2013.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Significant estimates include the valuation of inventory, measurement of stock based compensation and valuation of deferred tax assets. Actual results could materially differ from these estimates.
	Revenue Recognition
	The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) title or rights have transferred; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company uses contracts and customer purchase orders to determine the existence of an arrangement. The Company uses contractual terms, shipping documents and third-party proof of delivery to verify that title or rights have transferred. The Company assesses whether the fee is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection is not reasonably assured, then the recognition of revenue is deferred until collection becomes reasonably assured, which is generally upon receipt of payment.
	The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection or product return rights, outside of standard warranties. The Company includes shipping and handling costs in cost of product sales.
	Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, subject to satisfaction of all revenue recognition criteria at that time.  Revenue generated from license fees and performing development services is recognized when it is earned and non-refundable upon receipt of payments, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as the related development expenses plus overhead costs for certain project activities are incurred.
	Inventories
	Inventories are recorded at the lower of cost or market on a first-in, first-out basis. The Company periodically assesses the recoverability of all inventories, including materials, work-in-process and finished goods, by comparing the cost of inventory to expected selling prices to determine whether adjustments for impairment are required.  Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions.  Reduced demand may result in the need for inventory write-downs in the near term. Inventory write-downs are charged to cost of product sales and establish a lower cost basis for the inventory.
	Risks and Uncertainties
	The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities.

Note_2_Stockholders_Equity

Note 2 - Stockholders' Equity	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 2 - STOCKHOLDERS' EQUITY
	Common Stock
	On August 3, 2011, the Company entered into the At The Market Issuance Sales Agreement (the “ATM Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company may issue and sell up to $10.0 million of the Company’s common stock through MLV as the Company’s sales agent over the term of the ATM Agreement. The ATM Agreement provides that the offering of shares of the Company’s common stock pursuant to the ATM Agreement will terminate upon the earlier of (1) the sale of all common stock subject to the ATM Agreement, (2) August 2, 2014, and (3) termination of the ATM Agreement which may be effected by either MLV or the Company at any time upon 10 days’ notice to the other party. As of December 31, 2013, the Company had received net proceeds of $1.1 million, from the sale of an aggregate of 781,503 shares of common stock through MLV, including $0.3 million and $0.7 million received from MLV for the sale of an aggregate of 335,910 and 414,099 shares of common stock through MLV during the six months ended December 31, 2013 and 2012, respectively.
	Stock-Based Compensation
	Stock-based compensation expense related to employee and director share-based compensation plans, including stock options and restricted stock units, is measured on the grant date, based on the fair value-based measurement of the award and is recognized as an expense over the requisite service period which generally equals the vesting period of each grant. The Company recognizes compensation expense using the accelerated method.
	The Company selected the Black-Scholes option pricing model for determining the estimated fair value-based measurements of share-based awards. The use of the Black-Scholes model requires the use of assumptions including expected term, expected volatility, risk-free interest rate and expected dividends. The Company used the following assumptions in its fair value-based measurements:
		Three months ended						Six months ended
		December 31,						December 31,
		2013			2012			2013			2012
	Risk-free interest rate	0.91%	-	2.78%	0.44%	-	0.57%	0.91%	-	2.78%	0.44%	-	0.74%
	Dividend yield		-			-			-			-
	Weighted-average expected term (in years)	3.77	-	6	3.77	-	4.58	3.77	-	6	3.77	-	4.58
	Expected volatility	65.5%	-	80.60%	77.7%	-	83.2%	65.5%	-	80.60%	77.70%	-	84.30%
	The expected term of options granted is determined using the “simplified” method because the company concluded it does not have sufficient experience. Under this approach, the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term. The risk-free interest rate for the expected term of each option is based on a risk-free zero-coupon spot interest rate at the time of grant. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. The expected volatility is based on the Company’s historical stock price. Prior to the third quarter of fiscal year 2011, since the Company had limited historical data on volatility of its stock, the expected volatility was based on the volatility of similar entities (referred to as “guideline” companies). In evaluating similarity, the Company considered factors such as industry, stage of life cycle, size, and financial leverage. The Company estimates forfeitures in calculating the expense related to stock-based compensation. The Company recorded stock-based compensation expenses under ASC 718 of $0.5 million, or $0.01 per share, and $0.5 million, or $0.01 per share for the six months ended December 31, 2013 and 2012, respectively. Total compensation expense related to unvested awards not yet recognized is approximately $0.9 million at December 31, 2013, and is expected to be recognized over a weighted average period of 2.6 years.
	Included in the statement of operations are the following non-cash stock-based compensation expenses (in thousands):
		Three months ended						Six months ended
		December 31,						December 31,
		2013			2012			2013			2012
	Cost of product sales	$	54		$	26		$	70		$	51
	Research and development		76			74			48			138
	Selling, general and administrative		315			206			416			360
	Total	$	445		$	306		$	534		$	549

Note_3_Net_Loss_Per_Share

Note 3 - Net Loss Per Share	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 3 - NET LOSS PER SHARE
	Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period less the weighted-average unvested common shares subject to repurchase, and without consideration of potential common shares.  Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, less the weighted-average unvested common shares subject to repurchase, plus dilutive potential common shares for the period determined using the treasury-stock method.  For purposes of this calculation, options and warrants to purchase stock and unvested restricted stock awards are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive.
	The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share data):
		Three months ended						Six months ended
		December 31,						December 31,
		2013			2012			2013			2012
	Numerator:
	Net loss	$	(4,172	)	$	(4,192	)	$	(7,911	)	$	(8,332	)
	Denominator:
	Denominator for basic and diluted net loss per share		51,314			36,951			51,201			36,837
	Basic and diluted net loss per share	$	(0.08	)	$	(0.11	)	$	(0.15	)	$	(0.23	)
	The following table sets forth the outstanding securities not included in the diluted net loss per common share calculation as of December 31, 2013 and 2012, because their effect would be antidilutive (in thousands):
		As of December 31,
		2013			2012
	Options to purchase common stock		5,656			4,468
	Unvested restricted stock awards		46			74
	Warrants		3,991			3,991
	Total		9,693			8,533

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	6 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	NOTE 4 - FAIR VALUE MEASUREMENTS
	Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements,” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows:
	Level 1 -	Quoted prices in active markets for identical assets or liabilities.
	Level 2 -	Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	Level 3 -	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company does not have any liabilities that are measured at fair value on a recurring basis. All assets that are measured at fair value on a recurring basis have been segregated into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. These assets measured at fair value are summarized below (in thousands):
		As of December 31, 2013
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	3,841	$	—	$	—	$	3,841
	Short-term investments:
	Corporate debt securities		—		1,670		—		1,670
	Total assets at fair value	$	3,841	$	1,670	$	—	$	5,511
		As of June 30, 2013
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	5,462	$	—	$	—	$	5,462
	Short-term investments:
	Corporate debt securities		—		5,522		—		5,522
	Commercial paper		—		500		—		500
	Total assets at fair value	$	5,462	$	6,022	$	—	$	11,484
	Funds held in money market instruments are included in Level 1 as their fair values are based on market prices/quotes for identical assets in active markets.
	Corporate debt securities, federal agency bonds and certificates of deposits are valued primarily using market prices/quotes for similar assets and/or other sources of observable information and are included in Level 2. These inputs include market prices for comparable securities, bid/ask quotes, interest rate yields, and prepayment spreads.
	As of December 31, 2013, the Company’s material current financial assets and liabilities not carried at fair value, including its trade accounts receivable and accounts payable, were reported at their current carrying values which approximate fair value given the short-term nature of these instruments with maturity dates of less than one year. As of December 31, 2013, the Company’s note payable was reported at current carrying value which approximates fair value based on Level 3 unobservable inputs involving discounted cash flows and the estimated market rate of borrowing that could be obtained by companies with credit risk similar to the Company’s. See “Note 8 - Note Payable”.

Note_5_ShortTerm_Investments

Note 5 - Short-Term Investments	6 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Cash, Cash Equivalents, and Short-term Investments [Text Block]	'
	NOTE 5 – SHORT-TERM INVESTMENTS
	The Company held investments in marketable securities as of December 31, 2013, and June 30, 2013, with maturity dates of less than one year.
	The Company’s short-term investments consisted of the following (in thousands):
		As of December 31, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sale securities:
	Corporate debt securities	$	1,671	$	—	$	(1	)	$	1,670
		As of June 30, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sale securities:
	Corporate debt securities	$	5,527	$	—	$	(5	)	$	5,522
	Commercial paper		500		—		—			500
	Total	$	6,027	$	—	$	(5	)	$	6,022

Note_6_Inventories

Note 6 - Inventories	6 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	NOTE 6 - INVENTORIES
	Inventories consisted of the following (in thousands):
		December 31,		June 30,
		2013		2013
	Raw materials	$	308	$	473
	Work in progress		773		594
	Finished goods		306		390
	Total	$	1,387	$	1,457

Note_7_Distribution_License_De

Note 7 - Distribution, License, Development and Commercialization Agreements	6 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	NOTE 7 – DISTRIBUTION, LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTS
	Century
	On September 2, 2011, the Company signed a distribution agreement (the “Distribution Agreement”) with Century Medical, Inc. (“Century”) with respect to distribution of the Company’s planned microcutter products in Japan.  Under the terms of a secured note purchase agreement entered into at the time of the Distribution Agreement, Century agreed to loan the Company an aggregate of up to $4.0 million, with principal due five years after the first draw by the Company under the agreement, subject to certain conditions. Under this facility, the Company received $2.0 million on September 30, 2011, and the remaining $2.0 million on December 27, 2011. The note bears 5% annual interest which is payable quarterly in arrears on the last business day of March, June, September and December of each year through September 30, 2016, the maturity date when the total $4.0 million of principal becomes due.  In return for the loan commitment, the Company granted Century distribution rights to the Company’s planned microcutter product line in Japan, and a right of first negotiation for distribution rights in Japan to future products. Century is responsible for securing regulatory approval from the Ministry of Health in Japan for microcutter products. After approval for marketing in Japan, the Company would sell microcutter units to Century, which would then sell the microcutter devices to their customers in Japan.
	Proceeds from the note and granting the distribution rights were allocated to the note based on their aggregate fair value of $2.4 million at the dates of receipt. This fair value was determined by discounting cash flows using a discount rate of 18%, which the Company estimated was a market rate of borrowing that could be obtained by companies with credit risk similar to the Company’s. The remainder of the proceeds of $1.6 million was recognized as debt issuance discount and was allocated to the value of the distribution rights granted to Century under the Distribution Agreement and is included in deferred revenue. The deferred revenue will be recognized on a straight-line basis over the term of the Distribution Agreement, beginning upon the first sale by Century of microcutter products in Japan. As of December 31, 2013, and June 30, 2013, the balance of the loan was $2.9 million and $2.8 million net of debt issuance costs of $1.1 million and $1.2 million, respectively, and the distribution of the microcutter products had not begun for the respective periods.
	For the six months ended December 31, 2013 and 2012, sales of automated anastomosis systems to Century accounted for approximately 36% and 32%, respectively, of our total product sales. As of December 31, 2013, and June 30, 2013, Century accounted for approximately 14% and 33%, respectively, of the total accounts receivable balance.
	Intuitive Surgical
	On August 16, 2010, the Company entered into a license agreement with Intuitive Surgical (the “License Agreement”) pursuant to which the Company granted to Intuitive Surgical a worldwide, sublicenseable, exclusive license to use the Company’s intellectual property in the robotics field in diagnostic or therapeutic medical procedures, but excluding vascular anastomosis applications, for an upfront license fee of $9.0 million. The Company is also eligible to receive a contingent payment related to achieving a certain sales volume, as well as single-digit royalties on sales by Intuitive Surgical, its affiliates or its sublicensees of specified products covered by the Company’s patent rights, if any. Each party has the right to terminate the License Agreement in the event of the other party’s uncured material breach or bankruptcy. Following any termination of the License Agreement, the licenses granted to Intuitive Surgical will continue, and except in the case of termination for the Company’s uncured material breach or insolvency, Intuitive Surgical’s payment obligations will continue as well. Under the License Agreement, Intuitive Surgical has rights to improvements in the Company’s technology and intellectual property over a specified period of time.
	In addition, on the same date, the Company entered into a stock purchase agreement with Intuitive Surgical pursuant to which Intuitive Surgical paid $3.0 million to purchase from the Company an aggregate of 1,249,541 shares of the Company’s common stock. The net proceeds recorded to stockholders’ equity based upon the fair value of the Company’s common stock on August 16, 2010, were approximately $2.0 million after offering expenses.
	The Company determined that there were two substantive deliverables under the License Agreement representing separate units of accounting: license rights to technology that existed as of August 16, 2010, and license rights to technology that may be developed over the following three years. The $9.0 million upfront license payment and $1.0 million premium on the $3.0 million purchase of the Company’s common stock by Intuitive Surgical in connection with the License Agreement were aggregated and allocated to the two units of accounting based upon the relative estimated selling prices of the deliverables. The relative estimated selling prices of the deliverables were determined using a probability weighted expected return model with significant inputs relating to the nature of potential future outcomes and the probability of occurrence of future outcomes. Based upon the relative estimated selling prices of the deliverables, $9.0 million of the total consideration of $10.0 million was allocated to the license rights to technology that existed as of August 16, 2010, that has been recognized as revenue in the three months ended September 30, 2010, and $1.0 million was allocated to technology that may be developed over the following three years that was being recognized as revenue ratably over that three year period. In total, the revenue recognized for each of the six months ended December 31, 2013 and 2012, related to this arrangement was $41,000 and $168,000, respectively, and as of December 31, 2013, there was no deferred revenue related to this arrangement as the three years period has ended.
	Cook Incorporated
	In June 2007, the Company entered into, and in September 2007 and in June 2009 amended, a license, development and commercialization agreement with Cook Incorporated, to develop and commercialize a specialized device, which the Company refers to as the PFO Device, designed to close holes in the heart from genetic heart defects known as patent foramen ovales (“PFOs”). Under the agreement, Cook funded certain development activities and the Company and Cook jointly developed the PFO Device.  The Company’s significant deliverables under the arrangement were the license rights and the associated development activities.  These deliverables were determined to represent one unit of accounting as there was no stand-alone value to the license rights. If developed, Cook would receive an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to make, have made, use, sell, offer for sale and import the PFO Device. The Company did not record any license and development revenue under this agreement for the six months ended December 31, 2013 or 2012.  Amounts paid but not yet earned on the project are recorded as deferred revenue until such time as the related development expenses for certain project activities are incurred.  A total of $403,000 under this agreement had been recorded as deferred revenue as of December 31, 2013, and June 30, 2013. On January 6, 2010, the Company and Cook mutually agreed to suspend work on the PFO project and, accordingly, the Company does not anticipate receiving any additional payments or recording any additional revenue related to this agreement in the foreseeable future.

Note_8_Note_Payable

Note 8 - Note Payable	6 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 8 – NOTE PAYABLE
	In connection with the Distribution Agreement with Century, the Company entered into a secured note purchase agreement and a related security agreement pursuant to which Century agreed to loan to the Company up to an aggregate of $4.0 million (see Note 7, Distribution, License, Development and Commercialization Agreements).  Under this facility, the Company received $2.0 million on September 30, 2011, and the remaining $2.0 million on December 27, 2011. The note bears 5% annual interest which is payable quarterly in arrears on the last business day of March, June, September and December of each year through September 30, 2016, the maturity date when the total $4.0 million of principal becomes due. The debt issuance discount of approximately $1.6 million is reflected as a reduction in long-term debt and is being amortized as interest expense over the term of the note using the effective interest method. The note is secured by a substantial portion of the Company's assets, including the Company’s intellectual property related to the PAS-Port® Proximal Anastomosis System, but excluding all other intellectual property. As of December 31, 2013, and June 30, 2013, the balance of the loan was $2.9 million and $2.8 million net of debt issuance costs of $1.1 million and $1.2 million, respectively, and the distribution of the microcutter products had not begun for the respective periods.

Note_9_Amended_Lease_Agreement

Note 9 - Amended Lease Agreement	6 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	NOTE 9 – AMENDED LEASE AGREEMENT
	On November 11, 2010, the Company entered into an amendment to its facility lease (the “Lease Amendment”). Pursuant to the Lease Amendment, the term of the lease was extended by four years, through August 31, 2015, and the Company was granted an improvement allowance of $148,070 to be used in connection with the construction of alterations and refurbishment of improvements in the premises, which was used and reimbursed in November 2011, and January 2012. The leasehold improvement allowance will be recorded as a reduction of rent expense on a straight-line basis over the term of the lease. In addition, under the Lease Amendment, the Company was granted an option to further extend the lease for a period of two years beyond August 31, 2015 (the “Option Term”), with the annual rent payable by the Company during the Option Term to be equal to the annual rent for comparable buildings, as described in the Lease Amendment. Under the operating lease, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $100,000 was recorded as restricted cash in the condensed balance sheet as of December 31, 2013, and June 30, 2013, related to the letter of credit.
	Future minimum lease payments under the Company’s non-cancelable operating leases having initial terms of a year or more as of  December 31, 2013, including the Lease Amendment, are as follows (in thousands):
	Fiscal year ending June 30,	Operating
		Leases
	2014 (remaining six months)	$	335
	2015		690
	2016		118
	Total minimum lease payments	$	1,143

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Organization
	Cardica, Inc. (“Cardica” or the “Company”) was incorporated in the state of Delaware on October 15, 1997, as Vascular Innovations, Inc. On November 26, 2001, the Company changed its name to Cardica, Inc.  Historically, the Company’s business focused on the design, manufacture and marketing of proprietary automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. The Company has expanded and re-focused its business by emphasizing the development of a laparoscopic microcutter product line intended for use by thoracic, bariatric, colorectal and general surgeons.
	The Company is developing a microcutter product line based on its proprietary “staple-on-a-strip” technology, which expands its commercial opportunity into additional surgical markets. The Company’s microcutter product line consists of the currently commercially-available MicroCutter XCHANGE™ 30, a cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line, and products in development, including the MicroCutter XCHANGE™ 45, a cartridge based microcutter device with an 8 millimeter shaft and a 45 millimeter staple line, the MicroCutter XPRESS® 30, a true multi-fire endolinear stapling device, the MicroCutter FLEXCHANGE™ 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling, and the MicroCutter XPRESS® 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line specifically designed for the bariatric and thoracic surgery markets.
	The Company completed the design verification for and applied Conformité Européenne (the “CE Mark”) to the MicroCutter XCHANGE 30 in March 2012. The Company only received United States Food and Drug Administration (“FDA”) clearance,for the MicroCutter XCHANGE 30 and blue cartridge in January 2014, for use in multiple open or minimally-invasive surgical procedures for the transection, resection and/or creation of anastomoses in the small and large intestine, as well as the transection of the appendix. The blue cartridge is for use in medium thickness tissue. The Company submitted to the FDA a 510(k) for the white cartridge for use in thin tissue in the first quarter of calendar 2014. As part of the Company’s controlled commercial launch, on December 26, 2012, the Company made its first shipment to its distributor in Europe. The Company now has agreements with four distributors in Europe covering eight countries. The Company will continue to make enhancements and improvements to the MicroCutter XCHANGE 30 based on feedback from surgeons.
	To date, the Company generated product revenues almost exclusively from the sale of automated anastomotic systems, and has generated minimal revenues from the commercial sales of the MicroCutter XCHANGE 30, as it was introduced to the European market in December 2012. For the six months ended December 31, 2013, the Company generated net revenue of $1.7 million, including, $1.6 million from automated anastomotic systems and $79,000 from commercial sales of the MicroCutter XCHANGE 30.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Standards
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”), relating to Income Taxes (Topic 740), which provides guidance on the presentation of unrecognized tax benefits. The intent of ASU 2013-11 is to better reflect the manner in which an entity would settle at the reporting date any additional income taxes that would result from the disallowance of a tax position when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of ASU 2013-11 is not expected to have a material impact on the Company’s financial statements.
	In February 2013, the FASB issued ASU No. 2013-012, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income, which requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified in their entirety to net income. An entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. The Company adopted ASU No. 2013-02 in July 2013, and as a result, there was no material impact on the Company’s financial statements for the three and six months ended December 31, 2013.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Significant estimates include the valuation of inventory, measurement of stock based compensation and valuation of deferred tax assets. Actual results could materially differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) title or rights have transferred; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company uses contracts and customer purchase orders to determine the existence of an arrangement. The Company uses contractual terms, shipping documents and third-party proof of delivery to verify that title or rights have transferred. The Company assesses whether the fee is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection is not reasonably assured, then the recognition of revenue is deferred until collection becomes reasonably assured, which is generally upon receipt of payment.
	The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection or product return rights, outside of standard warranties. The Company includes shipping and handling costs in cost of product sales.
	Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, subject to satisfaction of all revenue recognition criteria at that time.  Revenue generated from license fees and performing development services is recognized when it is earned and non-refundable upon receipt of payments, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as the related development expenses plus overhead costs for certain project activities are incurred.
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are recorded at the lower of cost or market on a first-in, first-out basis. The Company periodically assesses the recoverability of all inventories, including materials, work-in-process and finished goods, by comparing the cost of inventory to expected selling prices to determine whether adjustments for impairment are required.  Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions.  Reduced demand may result in the need for inventory write-downs in the near term. Inventory write-downs are charged to cost of product sales and establish a lower cost basis for the inventory.

Note_2_Stockholders_Equity_Tab

Note 2 - Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three months ended						Six months ended
		December 31,						December 31,
		2013			2012			2013			2012
	Risk-free interest rate	0.91%	-	2.78%	0.44%	-	0.57%	0.91%	-	2.78%	0.44%	-	0.74%
	Dividend yield		-			-			-			-
	Weighted-average expected term (in years)	3.77	-	6	3.77	-	4.58	3.77	-	6	3.77	-	4.58
	Expected volatility	65.5%	-	80.60%	77.7%	-	83.2%	65.5%	-	80.60%	77.70%	-	84.30%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three months ended						Six months ended
		December 31,						December 31,
		2013			2012			2013			2012
	Cost of product sales	$	54		$	26		$	70		$	51
	Research and development		76			74			48			138
	Selling, general and administrative		315			206			416			360
	Total	$	445		$	306		$	534		$	549

Note_3_Net_Loss_Per_Share_Tabl

Note 3 - Net Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three months ended						Six months ended
		December 31,						December 31,
		2013			2012			2013			2012
	Numerator:
	Net loss	$	(4,172	)	$	(4,192	)	$	(7,911	)	$	(8,332	)
	Denominator:
	Denominator for basic and diluted net loss per share		51,314			36,951			51,201			36,837
	Basic and diluted net loss per share	$	(0.08	)	$	(0.11	)	$	(0.15	)	$	(0.23	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		As of December 31,
		2013			2012
	Options to purchase common stock		5,656			4,468
	Unvested restricted stock awards		46			74
	Warrants		3,991			3,991
	Total		9,693			8,533

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		As of December 31, 2013
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	3,841	$	—	$	—	$	3,841
	Short-term investments:
	Corporate debt securities		—		1,670		—		1,670
	Total assets at fair value	$	3,841	$	1,670	$	—	$	5,511
		As of June 30, 2013
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	5,462	$	—	$	—	$	5,462
	Short-term investments:
	Corporate debt securities		—		5,522		—		5,522
	Commercial paper		—		500		—		500
	Total assets at fair value	$	5,462	$	6,022	$	—	$	11,484

Note_5_ShortTerm_Investments_T

Note 5 - Short-Term Investments (Tables)	6 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Cash, Cash Equivalents and Investments [Table Text Block]	'
		As of December 31, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sale securities:
	Corporate debt securities	$	1,671	$	—	$	(1	)	$	1,670
		As of June 30, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sale securities:
	Corporate debt securities	$	5,527	$	—	$	(5	)	$	5,522
	Commercial paper		500		—		—			500
	Total	$	6,027	$	—	$	(5	)	$	6,022

Note_6_Inventories_Tables

Note 6 - Inventories (Tables)	6 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		December 31,		June 30,
		2013		2013
	Raw materials	$	308	$	473
	Work in progress		773		594
	Finished goods		306		390
	Total	$	1,387	$	1,457

Note_9_Amended_Lease_Agreement1

Note 9 - Amended Lease Agreement (Tables)	6 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Fiscal year ending June 30,	Operating
		Leases
	2014 (remaining six months)	$	335
	2015		690
	2016		118
	Total minimum lease payments	$	1,143

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended		195 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Revenue, Net (in Dollars)	$851,000	$874,000	$1,656,000	$1,759,000	'
Net Income (Loss) Attributable to Parent (in Dollars)	-4,172,000	-4,192,000	-7,911,000	-8,332,000	-161,500,000
Automated Anastomotic Systems [Member]	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Revenue, Net (in Dollars)	'	'	1,600,000	'	'
MicroCutter XCHANGE 30 [Member]	'	'	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Revenue, Net (in Dollars)	'	'	$79,000	'	'

Note_2_Stockholders_Equity_Det

Note 2 - Stockholders' Equity (Details) (USD $)	3 Months Ended		6 Months Ended		29 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Note 2 - Stockholders' Equity (Details) [Line Items]	'	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	$333,000	$817,000	$1,100,000
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	781,503
Allocated Share-based Compensation Expense	445,000	306,000	534,000	549,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in Dollars per share)	$0.01	$0.01	$0.01	$0.01	$0.01
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	900,000	'	900,000	'	900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'2 years 219 days	'	'
MLV [Member]	'	'	'	'	'
Note 2 - Stockholders' Equity (Details) [Line Items]	'	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	'	$700,000	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	335,910	414,099	'

Note_2_Stockholders_Equity_Det1

Note 2 - Stockholders' Equity (Details) - Black-Scholes Valuation Assumptions	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Minimum [Member]	'	'	'	'
Note 2 - Stockholders' Equity (Details) - Black-Scholes Valuation Assumptions [Line Items]	'	'	'	'
Risk-free interest rate	0.91%	0.44%	0.91%	0.44%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Weighted-average expected term (in years)	'3 years 281 days	'3 years 281 days	'3 years 281 days	'3 years 281 days
Expected volatility	65.50%	77.70%	65.50%	77.70%
Maximum [Member]	'	'	'	'
Note 2 - Stockholders' Equity (Details) - Black-Scholes Valuation Assumptions [Line Items]	'	'	'	'
Risk-free interest rate	2.78%	0.57%	2.78%	0.74%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Weighted-average expected term (in years)	'6 years	'4 years 211 days	'6 years	'4 years 211 days
Expected volatility	80.60%	83.20%	80.60%	84.30%

Note_2_Stockholders_Equity_Det2

Note 2 - Stockholders' Equity (Details) - Non-cash Stock-based Compensation (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Employee Service Share-based Compensation	$445	$306	$534	$549
Cost of Sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Employee Service Share-based Compensation	54	26	70	51
Research and Development Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Employee Service Share-based Compensation	76	74	48	138
Selling and Marketing Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Employee Service Share-based Compensation	$315	$206	$416	$360

Note_3_Net_Loss_Per_Share_Deta

Note 3 - Net Loss Per Share (Details) - Computation of Basic and Diluted Net Income (Loss) Per Share (USD $)	3 Months Ended		6 Months Ended		195 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Computation of Basic and Diluted Net Income (Loss) Per Share [Abstract]	'	'	'	'	'
Net loss (in Dollars)	($4,172)	($4,192)	($7,911)	($8,332)	($161,500)
Denominator for basic and diluted net loss per share	51,314	36,951	51,201	36,837	'
Basic and diluted net loss per share (in Dollars per share)	($0.08)	($0.11)	($0.15)	($0.23)	'

Note_3_Net_Loss_Per_Share_Deta1

Note 3 - Net Loss Per Share (Details) - Outstanding Securities Excluded from Net Income	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	9,693	8,533
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	5,656	4,468
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	46	74
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	3,991	3,991

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Fair Value Measurements (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Short-term investments:	'	'
Short-term investments	'	$6,022
Total assets at fair value	5,511	11,484
Fair Value, Inputs, Level 1 [Member]	'	'
Short-term investments:	'	'
Total assets at fair value	3,841	5,462
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]	'	'
Cash equivalents:	'	'
Cash equivalents	3,841	5,462
Fair Value, Inputs, Level 2 [Member]	'	'
Short-term investments:	'	'
Total assets at fair value	1,670	6,022
Money Market Funds [Member]	'	'
Cash equivalents:	'	'
Cash equivalents	3,841	5,462
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Short-term investments:	'	'
Short-term investments	1,670	5,522
Corporate Debt Securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	1,670	5,522
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	500
Commercial Paper [Member]	'	'
Short-term investments:	'	'
Short-term investments	$1,670	$500

Note_5_ShortTerm_Investments_D

Note 5 - Short-Term Investments (Details) - Short-Term Investments (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2013
Available-for-sale securities:	'	'
Amortized Cost	'	$6,027
Gross Unrealized Losses	'	-5
Fair Value	'	6,022
Commercial Paper [Member]	'	'
Available-for-sale securities:	'	'
Amortized Cost	1,671	500
Gross Unrealized Gains	'	0
Gross Unrealized Losses	-1	0
Fair Value	1,670	500
Corporate Debt Securities [Member]	'	'
Available-for-sale securities:	'	'
Amortized Cost	'	5,527
Gross Unrealized Losses	'	-5
Fair Value	$1,670	$5,522

Note_6_Inventories_Details_Inv

Note 6 - Inventories (Details) - Inventories (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$308	$473
Work in progress	773	594
Finished goods	306	390
Total	$1,387	$1,457

Note_7_Distribution_License_De1

Note 7 - Distribution, License, Development and Commercialization Agreements (Details) (USD $)

0 Months Ended

6 Months Ended

12 Months Ended

29 Months Ended

60 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

Dec. 27, 2011

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2013

Sep. 30, 2016

Dec. 31, 2013

Jun. 30, 2013

Dec. 27, 2011

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 16, 2010

Aug. 16, 2010

Sep. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Century Medical [Member]

Century Medical [Member]

Century Medical [Member]

Century Medical [Member]

Century Medical [Member]

Century Medical [Member]

Century Medical [Member]

Intuitive Surgical [Member]

Intuitive Surgical [Member]

Intuitive Surgical [Member]

Intuitive Surgical [Member]

Intuitive Surgical [Member]

Cook Incorporated [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Note 7 - Distribution, License, Development and Commercialization Agreements (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Secured Notes Payable

$2,000,000

$2,000,000

'

'

'

'

'

'

'

$2,000,000

$2,000,000

'

'

$4,000,000

'

'

'

'

'

'

Debt Instrument, Interest Rate During Period

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Related Parties

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Fair Value Disclosure

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumption for Fair Value of Assets or Liabilities that relate to Transferor's Continuing Involvement, Discount Rate

'

'

'

'

'

'

18.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

1,600,000

'

'

'

'

'

'

Notes Payable, Noncurrent

'

'

2,935,000

'

2,788,000

2,935,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Issuance Cost

'

'

1,100,000

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

'

'

'

'

'

14.00%

33.00%

'

'

36.00%

32.00%

'

'

'

'

'

'

'

Licenses Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,000,000

41,000

168,000

'

Common Stock, Value, Issued

'

'

51,000

'

51,000

51,000

'

'

'

'

'

'

'

'

3,000,000

3,000,000

'

'

'

'

Common Stock, Shares, Issued (in Shares)

'

'

51,482,524

'

51,068,614

51,482,524

'

'

'

'

'

'

'

'

1,249,541

1,249,541

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

333,000

817,000

'

1,100,000

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

Common Stock Premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Noncash or Part Noncash Divestiture, Amount of Consideration Received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

Deferred Revenue, Noncurrent

'

'

1,610,000

'

1,610,000

1,610,000

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Deferred Revenue, Current

'

'

$403,000

'

$444,000

$403,000

'

'

'

'

'

'

'

'

'

'

'

'

'

$403,000

Note_8_Note_Payable_Details

Note 8 - Note Payable (Details) (USD $)	0 Months Ended		6 Months Ended	12 Months Ended	60 Months Ended	0 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2011	Sep. 30, 2011	Dec. 31, 2013	Jun. 30, 2013	Sep. 30, 2016	Dec. 27, 2011	Sep. 30, 2011	Dec. 31, 2011
						Century Medical [Member]	Century Medical [Member]	Century Medical [Member]
Note 8 - Note Payable (Details) [Line Items]	'	'	'	'	'	'	'	'
Proceeds from Secured Notes Payable	$2	$2	'	'	'	$2	$2	$4
Debt Instrument, Interest Rate During Period	'	'	'	'	5.00%	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	'	'	4
Debt Instrument, Unamortized Discount	'	1.6	'	'	'	'	'	1.6
Senior Notes, Noncurrent	'	'	2.9	2.8	'	'	'	'
Debt Issuance Cost	'	'	$1.10	$1.20	'	'	'	'

Note_9_Amended_Lease_Agreement2

Note 9 - Amended Lease Agreement (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013	Nov. 11, 2010
Note 9 - Amended Lease Agreement (Details) [Line Items]	'	'	'
Leasehold Improvements, Gross	'	'	$148,070
Restricted Cash and Cash Equivalents	104,000	104,000	'
Building [Member]	'	'	'
Note 9 - Amended Lease Agreement (Details) [Line Items]	'	'	'
Restricted Cash and Cash Equivalents	$100,000	$100,000	'

Note_9_Amended_Lease_Agreement3

Note 9 - Amended Lease Agreement (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Minimum Lease Payments [Abstract]	'
2014 (remaining six months)	$335
2015	690
2016	118
Total minimum lease payments	$1,143